Evommune says EVO756 Phase 2b trial in chronic spontaneous urticaria misses primary endpoint

Evommune, Inc.

Evommune, Inc.

EVMN

0.00
  • Evommune reported top-line Phase 2b results for oral EVO756 in chronic spontaneous urticaria.
  • The trial missed its main efficacy goal, undermining the case to pursue EVO756 in this indication.
  • Management plans to continue development of EVO756 in atopic dermatitis, with top-line Phase 2b data expected in Q3 2026.
  • A Phase 2b migraine prevention study has begun screening, with patient dosing expected to start soon.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606290830BIZWIRE_USPR_____20260629_BW470075) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.